Health & Fitness:Medicine
The status of therapy of heart disease in America with Dr. Simon H. Stertzer
Dr. Simon H. Stertzer, Professor Emeritus at Stanford University School of Medicine and Chairman of the Board at BioCardia, a clinical-stage biotech-regenerative medicine company that develops innovative therapeutics for the treatment of cardiovascular disease joins eHealth Radio and the Heart Health and Health News Channels.
Listen to interview with host Eric Michaels & guest Dr. Simon H. Stertzer discuss the following:
Simon H. Stertzer, M.D. is Professor of Medicine, Emeritus, at Stanford University School of Medicine, and is currently Chairman of the Board of Directors at BioCardia®, Inc., a clinical-stage biotech-regenerative medicine company that develops innovative therapeutics for the treatment of cardiovascular disease.
In 1964, Simon Stertzer performed the first selective coronary arteriogram in New York City. He pioneered the subspecialty of Interventional Cardiology by performing the first coronary balloon angioplasty in the United States, in 1978. He has performed more than 12,500 cardiac interventions and has worked alongside others to develop new technologies for the improvement of patient care.
Dr. Stertzer has contributed to research and advancement in rotational atherectomy, cardiac stents, drug delivery stents, cardiac transplant molecular diagnostics, and most recently, transendocardial stem cell implantation in ischemic heart failure. His bibliography contains more than 140 peer-reviewed articles.
Dr. Stertzer co-founded BioCardia in 1999, and was a founder and board member of Arterial Vascular Engineering, an angioplasty balloon and stent company acquired by Medtronic Inc..
Simon Stertzer received his Doctor of Medicine degree from New York University, after a Bachelor of Arts degree in Humanities from Union College. He had previously earned a Certificat de Physiologie from University of Paris (Sorbonne).
About BioCardia®, Inc.
BioCardia®, Inc. is helping lead the way to new treatments of heart failure using the direct injection of cells and agents into the heart muscle. BioCardia is a clinical-stage, regenerative biotechnology company that develops novel therapeutics to treat cardiovascular disease. The treatment modalities include a system of personalized screenings to determine which patients are most likely to benefit from intramyocardial injection of therapeutic agents.
It is Free